| Literature DB >> 35116373 |
Jun Dong1, Guo-Dong Wang1, Hong-Zhi Wang1.
Abstract
BACKGROUND: To explore the clinical profiles and outcomes of patients with acute respiratory failure (ARF) after esophagectomy.Entities:
Keywords: Acute respiratory failure (ARF); TNM stage; anastomotic leakage; esophagectomy
Year: 2021 PMID: 35116373 PMCID: PMC8799240 DOI: 10.21037/tcr-21-1505
Source DB: PubMed Journal: Transl Cancer Res ISSN: 2218-676X Impact factor: 1.241
Reasons to ARF after esophagectomy
| Cause | Cases | Mortality in ICU | Mortality within 90 days |
|---|---|---|---|
| Anastomotic leakage | 17 | 11.76% (n=2) | 23.53% (n=4) |
| Pneumonia | 9 | 10.00% (n=1) | 40.00% (n=4) |
| Vocal cords paralysis | 7 | 0.00% | 0.00% |
| Sputum plugging | 7 | 0.00% | 0.00% |
| PE | 4 | 0.00% | 0.00% |
| ARDS | 3 | 33.33% (n=1) | 33.33% (n=1) |
| AECOPD | 3 | 0.00% | 33.33% (n=1) |
| Delay of recovery | 3 | 0.00% | 0.00% |
| Atelectasis | 3 | 0.00% | 0.00% |
| GB Syndrome | 2 | 0.00% | 0.00% |
| Phrenic nerve injury | 2 | 0.00% | 0.00% |
| AHF | 2 | 0.00% | 0.00% |
| Total | 62 | 6.45% (n=4) | 16.13% (n=10) |
ARF, acute respiratory failure; PE, Pulmonary embolism; ARDS, acute respiratory distress syndrome; AECOPD, acute exacerbations of chronic obstructive pulmonary disease; GB Syndrome, Guillain-Barre Syndrome; AHF, acute heart failure.
Figure 1ARF time distribution. ARF, acute respiratory failure; PE, pulmonary embolism; ARDS, acute respiratory distress syndrome; AECOPD, acute exacerbations of chronic obstructive pulmonary disease; AHF, acute heart failure.
Differences between survivors with non-survivors before operation
| Characteristic | Mortality in ICU | 90-day mortality | |||||
|---|---|---|---|---|---|---|---|
| Non-survival (n=4) | Survival (n=58) | P value | Non-survival (n=10) | Survival (n=52) | P value | ||
| Age (year) | 61.50±6.19 | 63.48±7.66 | 0.615 | 63±5.14 | 63.42±7.96 | 0.873 | |
| Gender | 0.433 | 0.382 | |||||
| Male | 75% (n=3) | 87.9% (n=51) | 80% (n=8) | 88.5% (n=46) | |||
| Female | 25% (n=1) | 12.1% (n=7) | 20% (n=2) | 11.5% (n=6) | |||
| BMI (kg/m2) | 22.98±2.80 | 23.75±3.79 | 0.692 | 22.62±2.73 | 23.90±3.87 | 0.323 | |
| TNM stage | |||||||
| T | 0.644 | 0.839 | |||||
| 0 | 0 | 3.4% (n=2) | 0 | 3.8% (n=2) | |||
| 1 | 0 | 19.0% (n=11) | 30% (n=3) | 15.4% (n=8) | |||
| 2 | 50% (n=2) | 20.7% (n=12) | 20% (n=2) | 23.1% (n=12) | |||
| 3 | 50% (n=2) | 48.3% (n=28) | 40% (n=4) | 50% (n=26) | |||
| 4 | 0 | 6.9% (n=4) | 10% (n=1) | 5.8% (n=3) | |||
| x | 0 | 1.7% (n=1) | 0 | 1.9% (n=1) | |||
| N | 0.103 | ||||||
| 0 | 25% (n=1) | 70.7% (n=41) | 30% (n=3) | 75% (n=39) | |||
| 1 | 50% (n=2) | 15.5% (n=9) | 30% (n=3) | 15.4% (n=8) | |||
| 2 | 0 | 6.9% (n=4) | 0 | 7.7% (n=4) | |||
| 3 | 25% (n=1) | 6.9% (n=4) | 40% (n=4) | 1.9% (n=1) | |||
| Pathology | 1.000 | 0.317 | |||||
| Squamous cell carcinomas | 100% (n=4) | 93.1% (n=54) | 90% (n=9) | 94.2% (n=49) | |||
| Adenocarcinoma | 0 | 3.4% (n=2) | 0 | 3.8% (n=2) | |||
| small cell carcinoma | 0 | 1.7% (n=1) | 0 | 1.9% (n=1) | |||
| Signet ring cell carcinoma | 0 | 1.7% (n=1) | 10% (n=1) | 0 | |||
| Smoking history | 0.728 | 0.507 | |||||
| Yes | 75% (n=3) | 74.1% (n=43) | 70% (n=7) | 75% (n=39) | |||
| No | 25% (n=1) | 25.9% (n=15) | 30% (n=3) | 25% (n=13) | |||
| Drinking history | 0.411 | 0.279 | |||||
| Yes | 75% (n=3) | 55.2% (n=32) | 70% (n=7) | 53.8% (n=28) | |||
| No | 25% (n=1) | 44.8% (n=26) | 30% (n=3) | 46.2% (n=24) | |||
| Chemotherapy before operation | 0.533 | 0.634 | |||||
| Yes | 50% (n=2) | 39.7% (n=23) | 40% (n=4) | 40.4% (n=21) | |||
| No | 50% (n=2) | 60.3% (n=35) | 60% (n=6) | 59.6% (n=31) | |||
| Hypertension | 0.553 | 0.229 | |||||
| Yes | 25% (n=1) | 36.2% (n=21) | 20% (n=2) | 38.5% (n=20) | |||
| No | 75% (n=3) | 63.8% (n=37) | 80% (n=8) | 61.5% (n=32) | |||
| DM | 0.342 | 0.246 | |||||
| Yes | 25% (n=1) | 8.6% (n=5) | 20% (n=2) | 7.7% (n=4) | |||
| No | 75% (n=3) | 91.4% (n=53) | 80% (n=8) | 92.3% (n=48) | |||
| CHD | 0.816 | 0.584 | |||||
| Yes | 0 | 5.2% (n=3) | 0 | 5.8% (n=3) | |||
| No | 100% (n=4) | 94.8% (n=55) | 100% (n=10) | 94.2% (n=49) | |||
| Biomarkers before operation | |||||||
| WBC (×109/L) | 5.85±1.82 | 6.67±2.66 | 0.548 | 6.00±1.33 | 6.74±2.79 | 0.421 | |
| HGB (g/L) | 142.75±23.81 | 138.62±18.35 | 0.670 | 141.2±27.80 | 138.44±16.53 | 0.670 | |
| PLT (×109/L) | 223.5±79.66 | 209.79±62.96 | 0.680 | 201±73.70 | 212.54±61.94 | 0.603 | |
| AST (IU/L) | 20.25±5.12 | 21.83±6.01 | 0.611 | 20.0±3.56 | 22.06±6.25 | 0.319 | |
| ALT (IU/L) | 17.00±2.00 | 16.90±9.28 | 0.982 | 16.50±5.38 | 16.98±9.55 | 0.878 | |
| TBIL (µmol/L) | 13.40±6.21 | 16.33±20.00 | 0.773 | 29.53±45.39 | 13.40±4.69 | 0.290 | |
| DBIL (µmol/L) | 4.78±2.12 | 6.11±18.71 | 0.888 | 18.04±43.59 | 3.57±1.22 | 0.321 | |
| TP (g/L) | 73.48±4.29 | 70.96±7.06 | 0.487 | 71.13±8.66 | 71.12±6.61 | 0.999 | |
| ALB (g/L) | 47.28±3.50 | 44.44±5.49 | 0.315 | 43.85±8.85 | 44.78±4.55 | 0.622 | |
| Cr (µmol/L) | 71.00±15.85 | 74.91±20.22 | 0.707 | 64.67±26.45 | 76.58±18.06 | 0.083 | |
| BUN (mmol/L) | 5.34±1.06 | 6.87±7.79 | 0.699 | 11.57±18.48 | 5.85±1.57 | 0.353 | |
| Lung function | |||||||
| Ventilation function impaired | 0.161 | 0.109 | |||||
| Yes | 33.3% (n=1) | 76.5% (n=39) | 50% (n=4) | 78.3% (n=36) | |||
| No | 66.7% (n=2) | 23.5% (n=12) | 50% (n=4) | 21.7% (n=10) | |||
| Diffusion function impaired | 0.534 | 0.17 | |||||
| Yes | 0 | 19.6% (n=10) | 100% (n=8) | 78.3% (n=36) | |||
| No | 100% (n=3) | 80.4% (n=41) | 0 | 21.7% (n=10) | |||
| Echocardiography | |||||||
| LVEF | 61.00±1.41 | 65.93±5.54 | 0.220 | 64.67±4.84 | 65.88±5.65 | 0.622 | |
| E/A ≥1 | 100% (n=1) | 35.7% (n=15) | 0.372 | 60% (n=3) | 34.2% (n=13) | 0.260 | |
| E/A <1 | 0 | 64.3% (n=27) | 40.0% (n=2) | 65.8% (n=25) | |||
DM, diabetes mellitus; CHD, coronary heart disease; LVEF, left ventricular ejection fraction; E/A, E wave A wave ratio.
Differences between survivors with non-survivors during operation
| Operation characteristic | Mortality in ICU | 90-day mortality | |||||
|---|---|---|---|---|---|---|---|
| Non-survival | Survival | P value | Non-survival | survival | P value | ||
| Operation | 1.000 | 1.000 | |||||
| McKeown | 75% (n=3) | 60.3% (n=35) | 60% (n=6) | 61.5% (n=32) | |||
| Ivor-Lewis operation | 25% (n=1) | 36.2% (n=21) | 40% (n=4) | 34.6% (n=18) | |||
| Sweet | 0 | 3.4% (n=2) | 0 | 3.8% (n=2) | |||
| Operation time (min) | 312.50±132.00 | 342.84±100.94 | 0.570 | 343.00±134.42 | 340.48±96.38 | 0.944 | |
| Fluid | |||||||
| Colloidal fluid (mL) | 1,125.00±250.00 | 1,022.41±380.69 | 0.599 | 1,200.00±483.05 | 996.15±344.12 | 0.114 | |
| Crystalloid fluid (mL) | 1,925.00±722.84 | 2,163.79±579.08 | 0.435 | 2,095.00±506.87 | 2,158.65±603.07 | 0.756 | |
| Fluid balance | 2,280.00±485.04 | 2,576.72±615.89 | 0.351 | 2,637.00±744.55 | 2,542.31±587.32 | 0.656 | |
| One-lung ventilation time (min) | 100.00±32.78 | 128.44±55.66 | 0.618 | 115.00±12.91 | 129.31±58.43 | 0.268 | |
| Blood loss (mL) | 245.00±136.99 | 201.72±142.95 | 0.560 | 248.00±220.19 | 196.15±122.81 | 0.294 | |
Patients severity
| Patients severity | Mortality in ICU | 90-day mortality | |||||
|---|---|---|---|---|---|---|---|
| Non-survival | Survival | P value | Non-survival | Survival | P value | ||
| Lactic acid clearance rate (%) | 38.58±40.69 | 26.20±39.37 | 0.545 | 33.89±29.52 | 225.68±40.83 | 0.463 | |
| Organ dysfunction | 0.011 | 0.002 | |||||
| Yes | 100% (n=4) | 29.3% (n=17) | 80% (n=8) | 25% (n=13) | |||
| No | 0 | 70.7% (n=41) | 20% (n=2) | 75% (n=39) | |||
| APACHE II score | 20.75±7.50 | 14.72±6.27 | 0.071 | 19.60±8.62 | 14.25±5.66 | 0.015 | |